Table of Contents Author Guidelines Submit a Manuscript
International Journal of Endocrinology
Volume 2014, Article ID 142468, 6 pages
http://dx.doi.org/10.1155/2014/142468
Research Article

The Association between 25-Hydroxyvitamin D and Hemoglobin A1c Levels in Patients with Type 2 Diabetes and Stage 1–5 Chronic Kidney Disease

1Department of Endocrinology and Nutrition, University Hospital of Amiens, 80054 Amiens, France
2INSERM Unit 1088, Jules Verne University of Picardie, 80037 Amiens, France
3Bone Biology and Endocrine Division, University Hospital of Amiens, 80054 Amiens, France
4Clinical Research Center, University Hospital of Amiens, 80054 Amiens, France
5Department of Clinical Nephrology, University Hospital of Amiens, 80054 Amiens, France

Received 28 May 2014; Revised 18 July 2014; Accepted 14 August 2014; Published 27 August 2014

Academic Editor: Andreas Tomaschitz

Copyright © 2014 Farshad Kajbaf et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. A. S. Dusso, A. J. Brown, and E. Slatopolsky, “Vitamin D,” American Journal of Physiology, vol. 289, no. 1, pp. F8–F28, 2005. View at Publisher · View at Google Scholar · View at Scopus
  2. M. F. Holick, “Vitamin D status: measurement, interpretation, and clinical application,” Annals of Epidemiology, vol. 19, no. 2, pp. 73–78, 2009. View at Publisher · View at Google Scholar · View at Scopus
  3. M. Flores, “A role of vitamin D in low-intensity chronic inflammation and insulin resistance in type 2 diabetes mellitus?” Nutrition Research Reviews, vol. 18, no. 2, pp. 175–182, 2005. View at Publisher · View at Google Scholar · View at Scopus
  4. G. N. Thomas, B. Ó. Hartaigh, J. A. Bosch et al., “Vitamin D levels predict all-cause and cardiovascular disease mortality in subjects with the metabolic syndrome: the Ludwigshafen risk and cardiovascular health (LURIC) study,” Diabetes Care, vol. 35, no. 5, pp. 1158–1164, 2012. View at Publisher · View at Google Scholar · View at Scopus
  5. K. C. Chiu, A. Chu, V. L. W. Go, and M. F. Saad, “Hypovitaminosis D is associated with insulin resistance and β cell dysfunction,” The American Journal of Clinical Nutrition, vol. 79, no. 5, pp. 820–825, 2004. View at Google Scholar · View at Scopus
  6. C. Gagnon, Z. X. Lu, D. J. Magliano et al., “Serum 25-hydroxyvitamin D, calcium intake, and risk of type 2 diabetes after 5 years: results from a national, population-based prospective study (the Australian diabetes, obesity and lifestyle study),” Diabetes Care, vol. 34, no. 5, pp. 1133–1138, 2011. View at Publisher · View at Google Scholar · View at Scopus
  7. A. G. Pittas, D. M. Nathan, J. Nelson et al., “Plasma 25-hydroxyvitamin D and progression to diabetes in patients at risk for diabetes: An ancillary analysis in the diabetes prevention program,” Diabetes Care, vol. 35, no. 3, pp. 565–573, 2012. View at Publisher · View at Google Scholar · View at Scopus
  8. S. Pilz, K. van den Hurk, G. Nijpels et al., “Vitamin D status, incident diabetes and prospective changes in glucose metabolism in older subjects: the Hoorn study,” Nutrition, Metabolism and Cardiovascular Diseases, vol. 22, no. 10, pp. 883–889, 2012. View at Publisher · View at Google Scholar · View at Scopus
  9. P. S. George, E. R. Pearson, and M. D. Witham, “Effect of vitamin D supplementation on glycaemic control and insulin resistance: a systematic review and meta-analysis,” Diabetic Medicine, vol. 29, no. 8, pp. e142–e150, 2012. View at Publisher · View at Google Scholar · View at Scopus
  10. S. Williams, K. Malatesta, and K. Norris, “Vitamin D and chronic kidney disease,” Ethnicity & Disease, vol. 19, supplement 5, pp. 8–11, 2009. View at Google Scholar · View at Scopus
  11. A. M. Hung and T. A. Ikizler, “Factors determining insulin resistance in chronic hemodialysis patients,” Contributions to Nephrology, vol. 171, pp. 127–134, 2011. View at Publisher · View at Google Scholar · View at Scopus
  12. D. R. Erlich, D. C. Slawson, and A. Shaughnessy, “Diabetes update: new drugs to manage type 2 diabetes,” FP essentials, vol. 408, pp. 20–24, 2013. View at Google Scholar · View at Scopus
  13. A. J. Scheen, “Clinical pharmacokinetics of metformin,” Clinical Pharmacokinetics, vol. 30, no. 5, pp. 359–371, 1996. View at Publisher · View at Google Scholar · View at Scopus
  14. S. El Messaoudi, G. A. Rongen, and N. P. Riksen, “Metformin therapy in diabetes: the role of cardioprotection,” Current atherosclerosis reports, vol. 15, no. 4, article 314, 2013. View at Publisher · View at Google Scholar · View at Scopus
  15. F. Kajbaf, P. Arnouts, M. de Broe, and J. D. Lalau, “Metformin therapy and kidney disease: a review of guidelines and proposals for metformin withdrawal around the world,” Pharmacoepidemiology and Drug Safety, vol. 22, pp. 1027–1035, 2013. View at Google Scholar
  16. J. Lalau, “Lactic acidosis induced by metformin: incidence, management and prevention,” Drug Safety, vol. 33, no. 9, pp. 727–740, 2010. View at Publisher · View at Google Scholar · View at Scopus
  17. F. Kajbaf and J. Lalau, “The prognostic value of blood pH and lactate and metformin concentrations in severe metformin-associated lactic acidosis,” BMC Pharmacology and Toxicology, vol. 14, article 22, 2013. View at Publisher · View at Google Scholar · View at Scopus
  18. C. Briet, M. Saraval-Gross, F. Kajbaf, A. Fournier, L. Hary, and J. D. Lalau, “Erythrocyte metformin levels in patients with type 2 diabetes and varying severity of chronic kidney disease,” Clinical Kidney Journal, vol. 5, pp. 65–67, 2012. View at Google Scholar
  19. J. Lalau and C. Lacroix, “Measurement of metformin concentration in erythrocytes: clinical implications,” Diabetes, Obesity and Metabolism, vol. 5, no. 2, pp. 92–98, 2003. View at Publisher · View at Google Scholar · View at Scopus
  20. A. S. Levey, J. Coresh, T. Greene et al., “Using standardized serum creatinine values in the modification of diet in renal disease study equation for estimating glomerular filtration rate,” Annals of Internal Medicine, vol. 145, no. 4, pp. 247–254, 2006. View at Publisher · View at Google Scholar
  21. M. F. Holick, “Vitamin D: a D-Lightful health perspective,” Nutrition Reviews, vol. 66, supplement 2, pp. S182–S194, 2008. View at Publisher · View at Google Scholar · View at Scopus
  22. C. Lacroix, P. Danger, and F. Wojciechowski, “Microassay of plasma and erythrocyte metformin by high-performance liquid chromatography,” Annales de Biologie Clinique, vol. 49, no. 2, pp. 98–101, 1991. View at Google Scholar · View at Scopus
  23. N. G. Forouhi, J. Luan, A. Cooper, B. J. Boucher, and N. J. Wareham, “Baseline serum 25-hydroxy vitamin d is predictive of future glycemic status and insulin resistance the medical research council ely prospective study 1990-2000,” Diabetes, vol. 57, no. 10, pp. 2619–2625, 2008. View at Publisher · View at Google Scholar · View at Scopus
  24. M. M. Soric, E. T. Renner, and S. R. Smith, “Effect of daily vitamin D supplementation on HbA1c in patients with uncontrolled type 2 diabetes mellitus: a pilot study,” Journal of Diabetes, vol. 4, no. 1, pp. 104–105, 2012. View at Publisher · View at Google Scholar · View at Scopus
  25. A. M. Ali, T. G. Awad, and O. M. Ali, “Effect of short-term vitamin D supplementation on glycemic control in newly- diagnosed type 2 diabetics,” Australian Journal of Basic and Applied Sciences, vol. 5, no. 6, pp. 1235–1239, 2011. View at Google Scholar · View at Scopus
  26. G. Zoppini, A. Galletti, G. Targher et al., “Glycated hemoglobin is inversely related to serum vitamin D levels in type 2 diabetic patients,” PLoS ONE, vol. 8, Article ID e82733, 2013. View at Google Scholar
  27. W. G. Tsiaras and M. A. Weinstock, “Factors influencing vitamin d status,” Acta Dermato-Venereologica, vol. 91, no. 2, pp. 115–124, 2011. View at Publisher · View at Google Scholar · View at Scopus
  28. J. A. Hirst, A. J. Farmer, R. Ali, N. W. Roberts, and R. J. Stevens, “Quantifying the effect of metformin treatment and dose on glycemic control,” Diabetes Care, vol. 35, no. 2, pp. 446–454, 2012. View at Publisher · View at Google Scholar · View at Scopus
  29. H. Pham, K. M. Utzschneider, and I. H. De Boer, “Measurement of insulin resistance in chronic kidney disease,” Current Opinion in Nephrology and Hypertension, vol. 20, no. 6, pp. 640–646, 2011. View at Publisher · View at Google Scholar · View at Scopus
  30. Q. Li, Y. Ju, T. Jin et al., “Haemoglobin A1c measurement in patients with chronic kidney disease,” Clinical Biochemistry, vol. 47, no. 6, pp. 481–484, 2013. View at Google Scholar
  31. J. Ly, R. Marticorena, and S. Donnelly, “Red blood cell survival in chronic renal failure,” The American Journal of Kidney Diseases, vol. 44, no. 4, pp. 715–719, 2004. View at Publisher · View at Google Scholar · View at Scopus
  32. S. Nurko, “Anemia in chronic kidney disease: causes, diagnosis, treatment,” Cleveland Clinic Journal of Medicine, vol. 73, no. 3, pp. 289–297, 2006. View at Publisher · View at Google Scholar · View at Scopus
  33. N. Selvaraj, Z. Bobby, and M. G. Sridhar, “Increased glycation of hemoglobin in chronic renal failure potential role of oxidative stress,” Archives of Medical Research, vol. 39, no. 3, pp. 277–284, 2008. View at Publisher · View at Google Scholar · View at Scopus